Akeso casts doubts on CD73 efforts
The company has ditched a trial of drebuxelimab plus ivonescimab.
BioNTech plans a spin-off
A new company will develop “next-generation mRNA” projects, amid another mRNA setback.
Roche flunks its first-line degrader test
Persevera is a bust, but Roche hasn’t given up on the front line.
Betta joins Revolution in pan-RAS inhibition
BPI-572270 enters clinical trials.
Servier makes a rare big buy
The company pays $2.5bn for Day One and its approved drug Ojemda.
